New Anticancer Drug: Genta Inc.’s G4460, An Antisense Drug Under Clinical Trial
Derived from Genta Incorporated (Nasdaq: GNTA)’s DNA/RNA Medicines Program, G4460 is the company’s new anticancer drug that uses antisense technology to target an oncogene known as c-myb that regulates key functions in cancer cells.
G4460 targets an oncogene product known as c-myb, which is a protein that directly binds to cellular DNA. C-myb is believed to regulate the expression of other genes that are involved in the growth and differentiation of cancer cells. Over-expression of c-myb blocks differentiation, promotes proliferation, and decreases apoptosis.
Recently, Genta Incorporated has initiated the Phase I clinical trial of G4460, an anticancer drug granted Orphan Drug Designation by the USFDA for treatment of patients with chronic myelocytic leukemia (CML).
Find more details from the full press release.
Tags: anticancer-drug, antisense-technology, chronic-myelocytic-leukemia, CML, G4460, Genta-IncorporatedRelated Stories
POSTED IN: Cancers of the blood & lymph, ~ Anti-cancer treatments ~
0 opinions for New Anticancer Drug: Genta Inc.’s G4460, An Antisense Drug Under Clinical Trial
No one has left a comment yet. You know what this means, right? You could be first!
Have an opinion? Leave a comment: